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Abstract  
Purpose: The use of novel and often expensive drugs offering limited survival benefit in 
advanced disease is controversial. Treatment recommendations are influenced by patient 
characteristics and trial data showing overall response rates (ORR), Progression Free 
Survival (PFS) and Overall Survival (OS). PFS is frequently the primary outcome in licensing 
studies. 
Patients and methods: As part of a longitudinal study Assessing the ‘VALue’ to patients of 
PROgression Free Survival (AVALPROFS), oncologists completed checklists at baseline 
following consultations with patients. Questions probed perceived clinical benefits of the 
drugs to populations in general. Patients completed study specific interview schedules at 
baseline, 6 weeks into treatment, and at withdrawal due to toxicity or progression. Patients 
also completed tumour and treatment specific quality of life questionnaires monthly for their 
time in the study. Only baseline results are reported here. 
Results: 32 UK oncologists discussed management options with 90 patients with 
heterogeneous advanced cancers. Oncologists’ estimates of medical benefit in general from 
treatment varied between 10-80%. They expected 46/90 (51%) of their patients to derive 
some clinical benefit from the prescribed treatment but were either unsure or expected none 
for 44/90 (49%). Predictions of life expectancy were variable but 62% (56/90) of patients 
were expected to survive longer with treatment. A majority of patients 51/90 (57%) had ‘no 
idea’ or were ‘unclear’ what PFS meant and 45/90 (50%) thought extension of life was the 
primary therapeutic aim of treatment.  
Conclusion: Discussions between doctors and patients with metastatic disease about future 
management plans and likely therapeutic gains are challenging. Factors influencing 
decisions about putative benefits of novel drugs are often applied inconsistently can be 
overly optimistic and may even contradict published data.  
 
Keywords: Oncologists’ decision making; patients; metastatic cancer; progression free 
survival estimates; therapeutic benefits 
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Introduction  
Progression Free Survival (PFS) does not directly measure how patients feel, function or 
survive, but is increasingly used as a primary end point in clinical trials of solid tumour 
oncology therapy and by default for licensing and marketing approval [1]. PFS is described 
by the National Cancer Institute as ‘the length of time during and after treatment for a 
disease such as cancer that a patient lives with the disease but it does not get worse’ [2]. 
Although PFS is an attractive end point for a variety of practical, methodological and 
financial reasons, it does not always result in overall survival (OS). [3-4]. 
There is debate as to whether or not, for a patient, a longer PFS results in discernible and 
meaningful clinical benefit, the main goal of palliative anti-cancer treatment. Establishing 
PFS depends on RECIST (Response Evaluation Criteria in Solid Tumours) criteria, which 
were developed to ensure some standardisation in the interpretation of drug activity on the 
tumour(s) in terms of stable disease, partial response or progression. The percentage 
increases or decreases in size shown on imaging and used by trialists were never intended 
to imply improvements or a decline in a patient’s overall well-being. In the past decade there 
has been a gradual increase in the number of publications from RCTs in common solid 
tumours where the primary end points have shifted from OS to PFS or time-to-progression. 
New ‘fast-tracked’ drug approvals are based increasingly upon surrogate end points with an 
expectation that post-marketing studies will later demonstrate other benefits such as OS. 
Completion of such studies is patchy, and can demonstrate that PFS is not necessarily a 
reliable surrogate for OS [4-5]. 
There are few data demonstrating that stabilisation of metastatic disease and/or a reduction 
in the burden of disease symptoms are really ‘worth’ any adverse treatment related side-
effects from a patient’s perspective [6-7]. Addressing this question directly is hard as studies 
often either omit the inclusion of well-validated and relevant Patient Reported Outcome 
(PRO) measures altogether or rely instead on physician reported CTCAE grades. Not only 
are these assessments fallible with little evidence of validity and dubious inter-rater reliability 
but they also fail to capture important information that might influence decision-making [8-9]. 
Rarely have studies examined whether or not patients even understand the meaning of 
concepts such as PFS [10]. 
Several reports show that patients with metastatic cancer need considerable help 
assimilating information about their disease and treatment goals; many have unrealistic 
perceptions of prognoses and the therapeutic intent of treatment which impacts decision -
making [11-13]. Discussing management options with patients with advanced cancer is 
challenging as there is not always a sufficient and comprehensive evidence-base for doctors 
Revision Friday, 26 August 2016 
4 
 
to be realistic in their presentation of benefits and harms [14] and there is a tendency for 
oncologists to overestimate survival for terminally ill patients [15]. 
This report focusses on oncologists’ views about the likely and estimated benefits of the 
treatment regimens they were offering to patients, together with individual patients’ 
understanding of therapeutic aims and expectations of treatment. 
Methods – materials 
 
Study design and participants 
AVALPROFS (Assessing the ‘VALue’ to patients of PROgression Free Survival) is a 
prospective, longitudinal study examining the ‘value’ that patients with advanced disease 
place on the drugs they are receiving that control the cancer, compared to the treatment 
related side-effects. Patients, aware of their diagnoses, who were about to commence drug 
treatment, which at the time of enrolment had shown only PFS or modest OS gains, were 
invited to participate. Researchers presented the study to interested cancer teams in the UK. 
Oncologists then contacted the Chief Investigator to enrol in the study. AVALPROFS was 
approved by London-Surrey Borders Research Ethics Committee (Ref: 14/LO/0045). 
Eligibility criteria  
 Oncologists who prescribed drugs which at the time the study commenced had 
demonstrated only PFS or modest (1-3 months) OS benefits 
 Patients able to be interviewed in English, diagnosed with metastatic cancer and a 
predicted life expectancy of at least 6 months, prescribed drugs as described above 
Procedures and measures 
Potential patient participants were recruited between March 2014 and July 2015 from 11 
cancer centres by their oncologists. Following the clinical consultation, patients who fulfilled 
the eligibility criteria for AVALPROFS, were informed briefly about the study, given a patient 
information sheet to take home and an expression of interest form (EOI) to complete if they 
wanted to learn more. Patients provided their contact details on the EOI form and a 
researcher telephoned 24 hours later to explain the study in more detail. 
 
Oncologists 
Immediately following the consultations, during which management options were discussed 
with patients, oncologists completed checklists probing the information that they had 
provided. A similar checklist had been used previously to gather data examining information 
given to patients with advanced disease embarking on Phase 1 trials [12]. This post 
consultation AVALPROFS checklist (shown in Appendix A) established the patient’s 
diagnosis, stage and site of metastasis, treatments received to date, and the drug discussed 
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at the most recent consultation. Oncologists then indicated whether or not they had outlined 
certain areas of information including the aims of treatment using- ‘yes’/’no’/’can’t 
recall’/’explained previously’- response options. They also estimated how much information 
they thought individual patients had understood. 
In section 4 of the checklist oncologists were asked what proportion of patients in general 
achieved some medical benefit from the drug and whether or not they expected each of their 
individual patients to derive any medical benefit. Response options were ‘yes’/ ‘no’/’don’t 
know’. Finally oncologists estimated the life expectancy of individual patients with and then 
without further treatment.  
Patients 
Participants were interviewed in their own homes (or by telephone if they preferred) by 
experienced researchers (LF, VJ, SC, VS) at baseline (within 2 weeks of the consultation) 
and again after six weeks of treatment. Further interviews were conducted at progression or 
if treatment was stopped due to toxicity. Patients stated the aims of treatment as they 
understood them and described any side-effects experienced. They were also asked to 
make ‘time trade-off’ (TTO) type assessments as to how worthwhile treatment would be or 
was, with different grades of side-effect against the time that the treatment might control the 
cancer.  
Participants also completed tumour and treatment specific quality of life questionnaires 
monthly up to 6 months. Written consent was obtained prior to the initial interview, which 
took place within two weeks from the consultation with the doctor.  
This report focusses only on data collected at baseline from the oncologists’ checklists and 
from participants’ first interviews. We compared oncologists’ views as to what was discussed 
in consultations with their patients’ interpretations of that information. Topic areas included 
results from recent tests or scans, therapeutic aims of the drug discussed, side-effects, 
whether or not the doctor used or explained the term PFS and patients’ understanding of 
that concept.  
Unlike the more usual time trade-off studies that probe hypothetical issues at one time point, 
this was a contemporaneous longitudinal observational study using real patients. Frequency 
counts and comparisons between responses were analysed using Chi2 statistical tests.  
Further analyses from the second and subsequent patient interviews, together with the 
Health Related Quality of Life Outcomes will be reported separately. 
Results 
Thirty-two oncologists (16 men; 16 women) participated. Twenty-six were consultants, 3 
specialist registrars and 3 senior fellows. Unfortunately as the consort diagram (Figure 1) 
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shows, although 139 patients were approached, only 90 were interviewed, half of whom died 
or became too ill to continue through to the 6 month follow-up.  
Demographics of the patients is shown in Table 1. Two patients received treatment within a 
clinical trial.  Oncologists reported that treatments being offered had already been mentioned 
in previous consultations with 59/90 (66%) patients.  
Table 2 shows the topics oncologists thought that they had explained or discussed during 
individual patient consultations. The majority (80/90; 89%) felt that they had checked their 
patients’ comprehension about the information given and 74/90 (82%) thought that their 
patients had fully or mostly understood the discussion. A majority of patients (87/90; 97%) 
reported receiving additional information leaflets about the treatments that they were 
starting.  
Oncologists’ expectations of medical benefit  
Oncologists expected that 46/90 (51%) of their patients would derive some medical benefit, 
and were unsure (39/90; 43%) or expected no benefit for others (5/90; 6%), all of whom 
nevertheless were prescribed treatments. Quotes from oncologists are shown below. 
“I explained to patient that the drug may work well and slow progression and re-
accumulation of pleural effusion, but also that it may not work” (everolimus & exemestane) 
“This disease has behaved unusually so far so difficult to predict” (cetuximab + cisplatin) 
“No way of being sure as no biomarker” (sunitinib) 
The responses to questions regarding putative medical benefits of treatments were 
inconsistent. For example in response to the question ‘What percentage of patients do you 
think will derive medical benefit from this drug?’, 7 oncologists prescribing EGFR-TK 
inhibitors for 24/30 patients with stage III/IV lung cancer estimated medical benefit of 
between 20-80% across 13/20 patients who had a proven gene mutation and between 10-
40% across 7/20 patients who had wild type.  The gene status was unknown or unavailable 
in 4 patients.  
Oncologists’ expectations of patients’ survival with and without treatment  
Two of the 90 patients who completed baseline assessments were too ill to even start 
treatment and 18/84 (21%) died within 6 months of study entry. The mean survival time for 
14/18 patients for whom the oncologists had shifted survival expectations with treatment in 
an optimistic direction was 89 days (sd. 41, Min-Max 25-177 days). Table 3 shows estimates 
of life expectancy without and then with treatment for lung cancer patients (who formed the 
largest tumour group) and for all other patients. It can be seen that oncologists estimated no 
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change in life expectancy for 34 patients receiving treatments, and an optimistic shift for the 
other 56 patients. Only 46/90 (51%) of oncologists had discussed other supportive care 
plans with patients. 
Patient reported cancer symptoms  
Two-thirds of patients reported one or more symptoms that they attributed to their cancer at 
baseline. The five most common were: pain (33/90, 37%), breathlessness (30/90, 33%), 
fatigue (23/90, 26%), cough (13/90, 14%), and loss of appetite (7/90, 8%).  
 
Side-effects from treatment 
Twenty five percent of patients had not started treatment at the time of the first interview, 
and 68/90 (75%) had received fewer than 2 weeks of treatment, yet 43/68 (63%) were 
experiencing side-effects. These were skin rash (11/43; 26%) fatigue (9/43; 21%), nausea 
(9/43; 21%); diarrhoea (9/43; 21%), mouth sores (5/43; 12%) and breathlessness (1/43; 2%). 
The worst side-effects most often anticipated by patients who had not commenced treatment 
(22/90), or had started treatment but were side-effect free (25/90), were diarrhoea, nausea, 
and breathlessness.  
 
Patients’ understanding and expectations about the phrase PFS 
Sixteen doctors said they employed the term PFS in 25 consultations but only 4 patients 
recalled its use. At interview most patients (51/90, 57%) had no idea or were unclear what 
the term PFS meant, 29/90 (32%) thought it was about ‘controlling cancer’ and 10/90 (11%) 
that it was about ‘extending life’, quotes from patients are shown below. 
 
“Hopefully tumour won’t grow, will give me longer time alive” 
“You’ve still got cancer but treatment is controlling it” 
“No idea what phrase means but sounds hopeful”     
 
Patients’ understanding of treatment aims 
Although the majority of patients 83/90 (92%) believed that the therapeutic aims of treatment 
were ‘to slow or stop the cancer’, half (45/90; 50%) also believed this meant ‘living longer’. 
Moreover, more than a third 35/90 (39%) said ‘living longer’ was the most important aim of 
treatment and two thirds (56/90, 62%) thought that their understanding of treatment aims 
would be achieved.  Almost a third (31/90) of patients, 64% (20/31) of whom were women, 
had searched the Internet to source or check information about the treatment offered. 
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The benefits patients expected from treatment varied; most (77/90, 86%) thought it would: - 
‘keep the cancer under control’, over half (49/90, 54%) ‘give them hope’, 40/90 (44%) ‘make 
them feel better’ and 35/90 (39%) ‘help them to live longer’.   
Expectation of a longer life as a treatment benefit was not influenced by age (older or 
younger than 65 years), sex, cancer symptoms, previous chemotherapy treatment or tumour 
type. 
Time trade-off questions 
Table 4 shows the responses to the time trade-off questions at baseline. The top 4 side-
effects nominated by patients and used for these questions were nausea (21/90; 23%), 
diarrhoea (20/90; 22%), fatigue (14/90; 16%) and breathlessness (13/90; 14%). As the 
possible severity of the side-effect increased, patients were significantly less inclined to feel 
that the benefit of controlling the cancer would be worthwhile (X2=75.6004; p < 0.00001). 
There was also an increase in the amount of time that patients would require the drug to 
control the cancer, for it to be considered a worthwhile treatment.  
 
Discussion 
Results from this study showed that oncologists’ general estimates of the likely therapeutic 
gains achievable from new treatments are sometimes at odds with available trial data and 
were inconsistent between individual patients. Some oncologists’ expectations regarding 
likely treatment benefits especially survival times were difficult to understand and we would 
assume therefore they were influenced by criteria other than published data. These may 
include anecdotal experience, personal bias or belief that the patient’s cancer represents a 
particular and preferential subset within the disease spectrum. The patients in this study 
were all considered suitable for treatment by their oncologists, but some were outside the 
limited eligibility criteria of trials. Oncologists may therefore have believed that the trial data 
(population) were not directly comparable to their patient’s disease (individual).  In some 
relatively rare cases, published trial data lags behind later evidence of improvement which 
may have influenced oncologists in AVALPROFS who were recruiting patients to other 
relevant studies (e.g. with the melanoma drug ipilimumab or pertuzumab in breast cancer) 
[16-18]. 
In AVALPROFS a heterogeneous group of patients were studied but lung cancer formed the 
largest group. Targeted agents were prescribed for 24 patients with lung cancer, only 13 of 
whom had an EGFR mutation. This finding is not unusual and corroborates results of a 
recent survey of 562 oncologists in 10 countries, showing that one in four patients with 
advanced lung cancer did not have EGFR-TK test results available before starting targeted 
Revision Friday, 26 August 2016 
9 
 
treatment [19]. For those patients who were EGFR-TK+, oncologists estimated benefits from 
treatment that ranged from 20 to 80% of patients in general; suggesting widely differing 
views. Moreover, where patients identified as wild type were prescribed EGFR-TK inhibitors, 
the oncologists’ estimates of the percentage of patients in general likely to benefit from such 
treatment varied, between 10-40%, which is greater than the published trial evidence [20]. 
Additionally, we found oncologists had expectations that patients having erlotinib would live 
longer. These data highlight incongruities and perhaps interplay of optimism. Drugs like 
erlotinib, vemurafenib and afatanib that target specific pathways have biomarkers 
(identifiable gene mutations) to help indicate usage, but other novel treatments such as 
ipilimumab work via different means and currently have no biomarker guidance, increasing 
the area of uncertainty for oncologists and their patients [16, 20, 21]. Neither NICE nor the 
manufacturers of drugs such as erlotinib recommend their use as treatment in end-of-life 
circumstances. [22, 23]. A significant minority (21%) of patients died within 6 months of 
entering AVALPROFS, with an average OS of 89 days (sd. 41). These findings are 
consistent with results from a retrospective study of 816 advanced cancer patients who had 
received targeted agents within the last 30 days of their lives. (The population studied in this 
report were mainly younger patients with haematological malignancies and those with lung 
cancer) [24]. Undue optimism about survival prospects held by oncologists may contribute to 
their prescribing habits, combined with a very real difficulty in having the honest and 
sometimes distressing discussions about prognosis. It has been shown that cancer patients 
with advanced disease who themselves hold overly optimistic assessments of their own 
survival often request active treatments rather than perhaps more beneficial supportive care 
[10]. 
Doctor-patient communications at these important decision points are further complicated by 
confusing medical terminology; health care professional jargon is often meaningless or 
misunderstood by the patient. It is perhaps not surprising that the phrase PFS was rarely 
used in consultations and when asked, most patients were unclear of its meaning. However, 
this does not explain why a majority of patients in the study thought that slowing or stopping 
the cancer growing, would then translate into them living longer.  PFS is a confusing term 
and the word ‘survival’ implied to some patients that the primary aim and likely benefit was to 
extend life. Progression Free Interval might be a more helpful phrase to use when discussing 
drugs with PFS or modest OS benefits.  
Agreement about what constitutes clinically meaningful benefit remains controversial even 
with the relatively robust endpoint of OS [25].The benefits achievable from targeted 
treatments, especially patient reported side-effects and quality of life are vital if treatment 
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effects are to be determined comprehensively [26]. In this study, side-effects occurred within 
two weeks of starting treatment and from the patients’ perspective the worst were nausea 
and diarrhoea. Despite this the vast majority believed the benefit of the drug in terms of 
controlling the cancer was worth Grade I (95%) and Grade II (88%) side-effects, but dropped 
to 44% at Grade III. 
Discussions with patients about disease progression and communicating the benefits of 
further active treatment in the palliative setting are challenging and nuanced so there is a 
need to balance many factors. It is essential for oncologists to retain perspective on what 
constitutes a meaningful benefit to patients, namely one that will bring improvements in 
symptoms and/or quality of life not just arrest of tumour burden on imaging or reductions in 
tumour markers.  
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Table 1:  Patient characteristics and drugs prescribed 
Characteristic N = 90 
Sex 
Male 
Female 
 
39 
51 
Age (Years) 
Mean (sd) 
Range 
 
65 (10.92) 
32-85 
Partner  
Yes 
 
58 
Employed 
Yes  
 
27 
Stage of disease 
III 
IV 
 
10 
80 
Past treatments  
Surgery 
Chemotherapy 
Radiotherapy 
Hormone therapy 
 
51 
44 
31 
13 
Current treatment  prescribed by tumour site 
Lung (30) afatinib (1) 
carboplatin + etoposide (1) or gemcitabine (1)  
pemetrexed  + carboplatin (2) or cisplatin (2)  
erlotinib (23) 
Melanoma (19) ipilimumab (15) 
dabrafenib (2) 
vemurafenib (2) 
Breast (18) bevacizumab + paclitaxel (2) 
eribulin (6)  
everolimus (1) + exemestane (4) 
TDM-1 (2) 
pertuzumab + docetaxel + trastuzumab (3) 
Renal (10) sunitinib (5) 
pazopanib (2) 
axitinib (2) 
everolimus (1) 
Gynae (7) bevacizumab (2) + carboplatin + paclitaxel (4)  or + 
gemcitabine (1) 
Head & Neck (3) cetuximab + cisplatin (2)  
cetuximab + carboplatin + 5FU (1) 
Colorectal (2) bevacizumab (1)  
bevacizumab + capecitabine (1) 
Sarcoma  (1) pazopanib (1) 
Site of metastasis 
Lung 
Bone 
Liver 
Brain 
Lymph nodes 
 
45 
23 
19 
 7 
19 
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Table 2: Section 3 of the consultation form 
Did you explain/discuss: 
 
Yes 
N (%) 
No 
N (%) 
Can’t 
recall  
N (%) 
The results of any tests or investigations?                                                                                                                                                                                                                                                                         81
(90%) 
9
(10%) 
0 
 (0%) 
The current status of the patient’s disease?                                                                                                                                                                                                                                                                         83  
(92%) 
7
(8%) 
0
 (0%) 
The drug/s that will be given?                                                                                                                                                                                                                                                                         90  
(100%) 
0
(0%) 
0
 (0%) 
The aims of the treatment? 89 
 (99%) 
1  
(1%) 
0 
 (0%) 
Explicitly use the terms progression free survival  
 or progression free interval? 
25  
(28%) 
64  
(71%) 
1 
 (1%) 
The side-effects of the drug/s? 89  
(99%) 
1  
(1%) 
0  
(0%) 
Ameliorative interventions for the side-effects? 69 
 (77%) 
20  
(22%) 
1  
(1%) 
Impact on life expectancy of the drug/s? 61 
 (68%) 
27 
 (30%) 
2 
 (2%) 
Effects on physical well-being of the drug/s? 80/89 
(90%) 
8/89  
(9%) 
1/89 
(1%) 
Effects on emotional/psychological well-being of 
treatment? (e.g. mood, positive/ negative outlook) 
23  
(26%) 
66  
(73%) 
1 
 (1%) 
Effects on social well-being of the treatment?                                                                   
(e.g. improve or hinder meeting/ interacting with people) 
23  
(26%) 
65  
(72%) 
2 
 (2%) 
Other care plans apart from the drug/s  (e.g. symptom 
relief, other treatment) 
46/89 
(52%) 
41/89  
(46%) 
2/89 
(2%) 
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Table 3: Expected effects of the drug/s 
 Estimates 
without treatment 
Estimates with treatment 
  
<3 mths 3-6 mths 7-12 mths >12 mths 
Lung  
(30) 
<3 mths 2 1   1 
3-6 mths 13  4 8 1 
7-12 mths 14   7 7 
>12 mths 1    1 
Other cancers 
(60) 
< 3 mths 5  1 2 2 
3-6 mths 14  2 6 6 
7-12 mths 23   1 22 
>12 mths 18    18 
 
 
Table 4: Participants’ responses to the trade-off questions from Interview A (n=90) 
The top 4 side-effects for trade-off were nausea (23%); diarrhoea (22%); fatigue (16%) and breathless 
(14%). 
 
 
1 See Appendix for booklet on Grades 
2 16 who were experiencing moderate side-effects were not asked this question  
3 The patient who said NO was not asked any further trade-off questions  
4 One person who said YES could not respond to the trade-off question  
5 Three who responded NO were not asked any further trade-off questions  
6 One person who said YES could not respond to the trade-off question  
7 35 who responded NO were not asked the trade-off question 
 
 
 
Is (or would) the benefit of the drug in 
terms of controlling the cancer be worth 
(the following Grade1 of severity)? 
With this Grade of side-effect how long do you 
require the treatment to control the cancer for 
you to consider it a worthwhile treatment for 
you? 
 N YES Probably NO N >1 
mth 
3 
mths 
6 mths >1yr > year 
Grade I 
side- 
effect? 
742 95% 
(70) 
4% 
(3) 
1%   
(13) 
72 75% 
(54) 
8%  
(6) 
13%  
(9) 
4% 
(3) 
 
Grade II 
side- 
effect? 
89 88% 
(784) 
9%       
 (8) 
3%  
(35) 
85 59% 
(50) 
12% 
(10) 
19% 
(16) 
9%       
(8) 
1%       
(1) 
Grade III 
side- 
effect? 
85 44% 
(376) 
15%     
(13) 
41% 
(357) 
49 49% 
(24) 
16% 
(8) 
22%    
(11) 
10%     
(5) 
2%       
(1) 
